Biomedical subjects

W Mielicki

Publications and source records attributed to W Mielicki.

5 recordsLinked to original sources

PubMed2002

Assessment of coagulation disorders and cancer procoagulant activity in patients with myelodysplastic syndromes.

Hemostatic disorders mainly due to thrombocytopenia represent an important clinical problem in patients with myelodysplastic syndromes (MDS). Much less is known about the possible coagulation abnormalities. Thirty patients with MDS were studied. Activity of cancer procoagulant (CP), concentrations of activation markers of coagulation and fibrinolysis such as thrombin-antithrombin complexes (TAT), prothrombin fragment 1+2 (F1+2) and D-dimers (DD) as well as standard coagulation tests were determined. Coagulation abnormalities concerned mainly patients with RAEB and RAEB-t. In this group the mean values of TATand F1+2 concentrations were significantly higher than in control indicating chronic coagulation activation similar to that observed in acute leukemias. CP activity in MDS patients did not differ from the control group.

Antithrombin III↗

PubMed1990

Cancer procoagulant in serum of rats during development of experimental epithelioma.

The activity of cancer procoagulant (CP) during the development of Guérin epithelioma was studied in the blood of Wistar rats. Blood was collected from the carotid artery and, after clotting, proteins adsorbing on aluminum hydroxide were removed from the serum. Then procoagulant activity was determined in the test system without factor VII by means of substrate S-2222 specific for factor Xa. A statistically significant increase in the activity of CP in serum was detected, coinciding with the period of intensive tumor growth (15th-25th day of disease).

Animals↗

PubMed1990

Procoagulant activity of human stomach and colon cancers.

Procoagulant activity in extracts from human stomach and colon cancers was examined, using chromogenic substrate S-2222. The activity of direct activator of factor X varied between 6 and 96% of total procoagulant activity of the tested extracts. The direct activator of factor X from stomach cancer was sensitive to heating and was inhibited by phenylmethylsulphonylfluoride and also by iodoacetic acid and HgCl2. Such results lead to the assumption that investigated activator is of enzymatic nature.

Blood Coagulation Factors↗

PubMed1989

Blood coagulation changes in rats during development of epithelioma.

Coagulation activity in the blood of rats during the development of Guerin epithelioma was studied. Clotting time, level of fibrinogen and some coagulation factors (II, V, VII + X) in the plasma were determined and thromboelastographic studies were performed. Two periods of blood hypercoagulability were observed in the process of epithelioma development. The first a short-term period, was noticed during the first days following the implantation of the neoplastic tissue. The second took place during the intensive growth of the primary tumor and metastases.

Animals↗

PubMed1988

Factor X-activating activity from Guerin epithelioma.

The procoagulant activity (PCA) was examined in extracts from primary tumor and metastases of experimental Guerin epithelioma transplanted into Wistar rats. PCA was evaluated by measurement of the level of activation of coagulation factor X using specific chromogenic substrate S-2222. We observed that extracts from both primary tumor and metastases were able to activate factor X in vitro. This activity was not factor VII-dependent, it was inhibited by phenylmethylsulfonyl fluoride (PMSF) and mercuric chloride, and in a smaller degree by p-chloromercuric benzoate (p-CMB) and iodoacetic acid (IAA). No difference between procoagulant activity in extracts from primary tumor and from metastases was observed.

Animals↗